Necitumumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | EGFR |
| Clinical data | |
| Trade names | Portrazza |
| ATC code | L01XC22 (WHO) |
| Identifiers | |
| CAS Number |
906805-06-9  |
| ChemSpider | none |
| UNII |
2BT4C47RUI  |
| KEGG |
D10018 |
| Chemical and physical data | |
| Formula | C6436H9958N1702O2020S42 |
| Molar mass | 144.84 kg/mol |
| (what is this?) (verify) | |
Necitumumab (proposed INN) is a recombinant human IgG1 monoclonal antibody used as an antineoplastic. It binds to the epidermal growth factor receptor (EGFR).[1] The US FDA approved necitumumab under the brand name Portrazza for use with gemcitabine and cisplatin in previously untreated metastatic squamous non-small-cell lung carcinoma (NSCLC).[2][3][4] It was counterproductive in non-squamous non-small-cell lung carcinoma.[4][5]
References
- ↑ International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy), World Health Organization.
- ↑ http://www.medscape.com/viewarticle/854952?nlid=91969_3663&src=wnl_edit_newsal&uac=78316PX&impID=899999&faf=1
- ↑ http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm474278.htm
- 1 2 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125547s000lbl.pdf
- ↑ http://www.medscape.com/viewarticle/840768
This article is issued from Wikipedia - version of the 9/1/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.